{"id":60776,"date":"2024-02-28T07:07:41","date_gmt":"2024-02-28T07:07:41","guid":{"rendered":"https:\/\/medsname.com\/tenvir-af\/"},"modified":"2026-05-21T05:27:39","modified_gmt":"2026-05-21T05:27:39","slug":"tenvir-af","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/tenvir-af\/","title":{"rendered":"Tenvir AF"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:16px 20px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin-top:0;\">Quick Answer &mdash; Tenvir AF (Tenofovir Alafenamide 25 mg)<\/h3>\n<ul>\n<li><strong>\u0395\u03bd\u03b5\u03c1\u03b3\u03cc \u03c3\u03c5\u03c3\u03c4\u03b1\u03c4\u03b9\u03ba\u03cc:<\/strong> tenofovir alafenamide fumarate (TAF) 25 mg, oral tablet, taken once daily with food.<\/li>\n<li><strong>\u039a\u03cd\u03c1\u03b9\u03b1 \u03ad\u03bd\u03b4\u03b5\u03b9\u03be\u03b7 \u03c3\u03b5 \u03b1\u03c5\u03c4\u03ae\u03bd \u03c4\u03b7\u03bd \u03ba\u03b1\u03c4\u03b1\u03c7\u03ce\u03c1\u03b7\u03c3\u03b7:<\/strong> chronic hepatitis B virus (HBV) infection in adults &mdash; long-term suppression with substantially less kidney and bone exposure than older TDF.<\/li>\n<li><strong>\u039c\u03b7\u03c7\u03b1\u03bd\u03b9\u03c3\u03bc\u03cc\u03c2 \u03b4\u03c1\u03ac\u03c3\u03b7\u03c2:<\/strong> nucleotide reverse-transcriptase inhibitor (NRTI). Same active metabolite as tenofovir disoproxil, but a different prodrug that releases tenofovir inside hepatocytes and lymphocytes.<\/li>\n<li><strong>Versus TDF:<\/strong> ~90% lower plasma tenofovir, ~6&ndash;7&times; higher intracellular drug. Same antiviral potency. Lower risk of renal toxicity and bone mineral density loss.<\/li>\n<li><strong>\u0391\u03c0\u03bf\u03c4\u03b5\u03bb\u03b5\u03c3\u03bc\u03b1\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1 \u03c3\u03b5 HBV:<\/strong> non-inferior to TDF for HBV DNA suppression at 96 weeks; significantly better renal and bone safety markers in head-to-head trials.<\/li>\n<li><strong>\u03a0\u03c1\u03bf\u03b5\u03b9\u03b4\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u03b3\u03b9\u03b1 \u03ad\u03be\u03b1\u03c1\u03c3\u03b7 HBV:<\/strong> severe acute exacerbation can occur on discontinuation. Never stop without specialist supervision.<\/li>\n<\/ul>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 <a href=\"https:\/\/medsbase.com\/el\/reviews\/\">\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd <a href=\"https:\/\/medsbase.com\/el\/medsbase-re-shipment-assurance-policy\/\"><strong>\u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n<h3>\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n<p>\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n<h2 class=\"wp-block-heading\">What Is Tenvir AF?<\/h2>\n<p>Tenvir AF is an oral tablet containing <strong>tenofovir alafenamide fumarate 25 mg<\/strong> (TAF), manufactured by Cipla. Each pack typically contains 30 film-coated tablets.<\/p>\n<p>TAF is the second-generation prodrug of tenofovir, designed to fix the renal and bone toxicity issues seen with the older TDF (tenofovir disoproxil) prodrug. The originator brand is <strong>Vemlidy<\/strong> (Gilead, FDA-cleared for chronic hepatitis B in 2016). Same active drug as TDF, dramatically different pharmacokinetics.<\/p>\n<h2 class=\"wp-block-heading\">What Is Tenvir AF Used For?<\/h2>\n<ul>\n<li><strong>Chronic hepatitis B (CHB) in adults<\/strong> &mdash; first-line oral antiviral, especially in patients with chronic kidney disease (CKD), osteoporosis, age &gt; 60, or pre-existing TDF-related renal\/bone toxicity.<\/li>\n<li><strong>\u03bc\u03cc\u03bb\u03c5\u03bd\u03c3\u03b7 \u03b1\u03c0\u03cc HIV-1<\/strong> &mdash; component of combination regimens (most commonly co-formulated with FTC, dolutegravir or bictegravir, or rilpivirine). Not used as monotherapy in HIV.<\/li>\n<li><strong>\u03a0\u03c1\u03bf\u03c6\u03cd\u03bb\u03b1\u03be\u03b7 \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03ad\u03ba\u03b8\u03b5\u03c3\u03b7 \u03c3\u03b5 HIV (PrEP)<\/strong> &mdash; the TAF + emtricitabine combination (Descovy) is approved for PrEP in cisgender men and transgender women; TDF\/FTC remains preferred for at-risk people who could become pregnant.<\/li>\n<\/ul>\n<p>TAF is <strong>\u03b4\u03b5\u03bd<\/strong> used to treat hepatitis C, herpes viruses, or any non-retroviral \/ non-HBV infection.<\/p>\n<h2 class=\"wp-block-heading\">Why TAF Instead of TDF?<\/h2>\n<p>TDF is rapidly hydrolysed in plasma to tenofovir, exposing the kidneys to high circulating drug levels for hours. TAF stays intact in plasma far longer because it is a more stable prodrug, and is preferentially activated by lymphocyte and hepatocyte intracellular esterases (cathepsin A, CES1). The net result:<\/p>\n<table style=\"border-collapse:collapse;width:100%;font-size:14px;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;\">Marker<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;\">TDF 300 mg<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;\">TAF 25 mg<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Plasma tenofovir AUC<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">High (reference)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">~90% \u03c7\u03b1\u03bc\u03b7\u03bb\u03cc\u03c4\u03b5\u03c1\u03b7<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">Intracellular TFV-DP in PBMCs<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Reference<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">~6&ndash;7&times; higher<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">eGFR decline at 96 wks (HBV)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Modest, dose-related<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Significantly less<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">Hip + spine BMD change<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Small reduction<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Less reduction; sometimes recovery on switch<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Lipid effect<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Mildly favourable (lipid-lowering)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Mildly unfavourable (raises LDL\/HDL)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The lipid effect is the one trade-off. In patients with established cardiovascular disease, TDF may be preferred. For most HBV patients with renal or bone risk factors, TAF is the cleaner long-term option.<\/p>\n<h2 class=\"wp-block-heading\">Dosage and How to Take Tenvir AF<\/h2>\n<ul>\n<li><strong>Chronic hepatitis B:<\/strong> one 25 mg tablet once daily with food.<\/li>\n<li><strong>HIV (combination regimens):<\/strong> 25 mg if combined with non-boosted agents; 10 mg if combined with a CYP3A inhibitor (cobicistat, ritonavir).<\/li>\n<\/ul>\n<p>Take with food &mdash; bioavailability rises by approximately 65% with a moderate-fat meal. Swallow whole. Missed doses: take as soon as remembered if within 18 hours; otherwise skip and resume the next scheduled tablet.<\/p>\n<p><strong>Renal-impairment dose adjustment:<\/strong> no adjustment required for CrCl &ge; 15 mL\/min. Below 15 mL\/min, only use in patients on chronic haemodialysis (TAF dosed after dialysis on dialysis days). TAF is not recommended in non-dialysis end-stage renal disease.<\/p>\n<p><strong>\u0397\u03c0\u03b1\u03c4\u03b9\u03ba\u03ae \u03b4\u03c5\u03c3\u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1:<\/strong> no adjustment for mild or moderate; not recommended in decompensated cirrhosis (Child-Pugh C).<\/p>\n<h2 class=\"wp-block-heading\">\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n<p><strong>\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2:<\/strong> headache (~10%), abdominal pain (~5%), fatigue, cough, nausea, back pain. Usually mild and self-limiting.<\/p>\n<p><strong>\u039b\u03b9\u03b3\u03cc\u03c4\u03b5\u03c1\u03bf \u03c3\u03c5\u03c7\u03bd\u03ac \u03b1\u03bb\u03bb\u03ac \u03c3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ac:<\/strong><\/p>\n<ul>\n<li><strong>Lipid changes<\/strong> &mdash; expect modest rise in LDL-C, HDL-C, total cholesterol, and triglycerides. Recheck lipids at 3 and 12 months. Consider statin therapy if cardiovascular risk is elevated.<\/li>\n<li><strong>\u0391\u03cd\u03be\u03b7\u03c3\u03b7 \u03b2\u03ac\u03c1\u03bf\u03c5\u03c2<\/strong> &mdash; HIV trials show several kg over 1&ndash;2 years on TAF-containing regimens vs TDF (regression of TDF&#8217;s mild lipid-lowering effect appears to drive part of this). Less established in HBV monotherapy.<\/li>\n<li><strong>Lactic acidosis with severe hepatomegaly<\/strong> &mdash; rare NRTI class effect; stop on unexplained progressive abdominal pain, rapid breathing, severe fatigue.<\/li>\n<li><strong>Severe acute hepatitis B exacerbation on stopping<\/strong> &mdash; same flare risk as TDF. Requires monitoring for at least 6 months after discontinuation.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03a6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n<ul>\n<li><strong>Strong P-gp inducers<\/strong> &mdash; rifampicin, rifabutin, carbamazepine, phenytoin, oxcarbazepine, St John&#8217;s wort &mdash; lower TAF exposure. Avoid co-administration.<\/li>\n<li><strong>CYP3A inhibitors<\/strong> &mdash; cobicistat, ritonavir &mdash; significantly raise TAF exposure. Use the 10 mg form if co-administered with a boosted PI\/INSTI regimen.<\/li>\n<li><strong>\u0386\u03bb\u03bb\u03b1 \u03bd\u03b5\u03c6\u03c1\u03bf\u03c4\u03bf\u03be\u03b9\u03ba\u03ac \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1<\/strong> &mdash; less of a concern than with TDF, but caution still advised with cidofovir, IV aminoglycosides, IV amphotericin B, high-dose NSAIDs.<\/li>\n<li><strong>Other tenofovir-containing products<\/strong> &mdash; do not combine TAF with TDF, adefovir, or another TAF-containing product.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Who Should Not Take Tenvir AF?<\/h2>\n<ul>\n<li>Known hypersensitivity to tenofovir alafenamide or any excipient<\/li>\n<li>Severe renal impairment (CrCl &lt; 15 mL\/min) not on chronic haemodialysis<\/li>\n<li>Decompensated cirrhosis (Child-Pugh C)<\/li>\n<li>Concurrent strong P-gp inducer where switching is not feasible<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u0391\u03c0\u03bf\u03b8\u03ae\u03ba\u03b5\u03c5\u03c3\u03b7<\/h2>\n<p>Store below 30&deg;C in the original bottle with desiccant. Protect from moisture. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n<h3 class=\"wp-block-heading\">Is Tenvir AF the same as Vemlidy?<\/h3>\n<p>Yes &mdash; same molecule (tenofovir alafenamide 25 mg), same indication (chronic hepatitis B), same once-daily dosing. Tenvir AF is Cipla&#8217;s licensed generic version. Vemlidy is the originator (Gilead).<\/p>\n<h3 class=\"wp-block-heading\">If TAF is better, why does anyone still take TDF?<\/h3>\n<p>Several reasons: TDF has a 20-year safety database; TDF lowers LDL cholesterol slightly (TAF does the opposite); pregnancy data is more mature for TDF; and TDF is materially cheaper. For young patients without renal or bone issues, TDF remains a perfectly reasonable first-line choice. TAF is preferred when renal or bone safety matters most.<\/p>\n<h3 class=\"wp-block-heading\">Can I switch from Tenvir (TDF) to Tenvir AF?<\/h3>\n<p>Yes, and many patients do, especially after years on TDF when small declines in eGFR or BMD become relevant. The switch is straightforward: stop TDF, start TAF the next day. Antiviral suppression is maintained because both deliver the same active metabolite. Renal markers usually improve within 3&ndash;6 months. Recheck eGFR, urine protein, phosphate at 3 months post-switch.<\/p>\n<h3 class=\"wp-block-heading\">Will Tenvir AF cure my hepatitis B?<\/h3>\n<p>No oral antiviral cures HBV. Tenofovir alafenamide suppresses replication so completely that viral DNA usually becomes undetectable and liver inflammation resolves &mdash; but the cccDNA template inside hepatocytes is not eliminated. Around 1&ndash;3% of patients per year achieve functional cure (HBsAg loss). For most patients, treatment is long-term.<\/p>\n<h3 class=\"wp-block-heading\">Should I expect weight gain on Tenvir AF?<\/h3>\n<p>HIV combination data show modest weight gain on TAF regimens vs TDF, of around 2&ndash;4 kg over 96 weeks. The effect is smaller in HBV monotherapy and is partly explained by reversal of TDF&#8217;s slight metabolic disadvantage. If weight gain is concerning, baseline lipid and glucose monitoring is reasonable.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Tenvir AF in pregnancy?<\/h3>\n<p>Pregnancy data for TAF is growing but is still less mature than for TDF. For HBV in late pregnancy (week 28+) to prevent vertical transmission, TDF is the preferred choice based on the larger safety database. If you are stable on TAF and become pregnant, discuss with your hepatologist before switching &mdash; the call depends on viral load, fibrosis stage, and trimester.<\/p>\n<h3 class=\"wp-block-heading\">Is Tenvir AF active against HIV resistance mutations?<\/h3>\n<p>TAF and TDF have an identical resistance profile because they deliver the same active metabolite. Both retain activity against most thymidine-analogue mutations (TAMs) but are reduced in efficacy against the K65R reverse-transcriptase mutation. Resistance testing should guide regimen choice when available.<\/p>\n<h3 class=\"wp-block-heading\">Do I need any blood tests before starting Tenvir AF?<\/h3>\n<p>Yes &mdash; baseline HBV DNA, HBeAg \/ anti-HBe, HBsAg, ALT\/AST, full blood count, eGFR, urinalysis (proteinuria), serum phosphate, lipid panel, and HIV antibody\/antigen test. Treatment monitoring then settles to every 3&ndash;6 months for stable patients.<\/p>\n<h3 class=\"wp-block-heading\">Does Tenvir AF interact with statins, blood-pressure drugs, or contraception?<\/h3>\n<p>No clinically significant interaction with statins, ACE inhibitors, ARBs, beta-blockers, calcium-channel blockers, or hormonal contraception. The few real interactions are with strong P-gp inducers (rifampicin, anticonvulsants) and CYP3A boosters (cobicistat, ritonavir).<\/p>\n<h3 class=\"wp-block-heading\">Where can I order Tenvir AF?<\/h3>\n<p>You can order Tenvir AF directly from MedsBase. We supply genuine Cipla stock with worldwide shipping. Treatment of chronic hepatitis B should be supervised by a hepatologist or gastroenterologist with HBV DNA, ALT, eGFR, and HBsAg\/anti-HBs monitoring at appropriate intervals.<\/p>\n<h2 class=\"wp-block-heading\">\u0391\u03c0\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u0395\u03c5\u03b8\u03c5\u03bd\u03ce\u03bd<\/h2>\n<p>The information on this page is for educational purposes and is not a substitute for professional medical advice. Treatment of chronic hepatitis B and HIV requires baseline workup, ongoing specialist monitoring, and individualised regimen choice. Do not start, stop, or switch tenofovir-based therapy without consulting a qualified clinician.<\/p>\n<p class=\"medsbase-bundle-link-2026-05-01\" data-marker=\"mb-bundle-link-prep-starter-pack\">Tenvir-AF (TAF\/FTC) handles HIV PrEP but does not cover bacterial STIs; if you&#8217;d like layered protection many users pair it with doxy-PEP \u2014 our <a href='\/el\/prep-starter-pack\/'>\u03a0\u03b1\u03ba\u03ad\u03c4\u03bf \u0388\u03bd\u03b1\u03c1\u03be\u03b7\u03c2 PrEP (Tenvir-EM + \u03b4\u03bf\u03be\u03c5\u03ba\u03c5\u03ba\u03bb\u03af\u03bd\u03b7 100 mg)<\/a> bundles the established TDF\/FTC PrEP regimen with doxycycline for syphilis, chlamydia, and gonorrhoea prevention.<\/p>\n<p class=\"medsbase-link-boost-2026-05-08\" data-marker=\"mb-link-boost-tenvir-em\">\u039f\u03b9 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd <a href=\"https:\/\/medsbase.com\/el\/tenvir-af\/\">Tenvir AF<\/a> for hepatitis B who also require HIV pre-exposure prophylaxis should note that <a href=\"https:\/\/medsbase.com\/el\/tenvir-em\/\">Tenvir EM (tenofovir disoproxil fumarate 300&nbsp;mg + emtricitabine 200&nbsp;mg)<\/a> is the approved dual-component PrEP regimen combining TDF with emtricitabine for comprehensive HIV prevention.<\/p>\n<p class=\"medsbase-link-boost-2026-05-10\" data-marker=\"mb-link-boost-avonza\">Clinics building ART formularies around <a href=\"https:\/\/medsbase.com\/el\/tenvir-af\/\">Tenvir AF (tenofovir alafenamide 25 mg)<\/a> as a renal-sparing backbone also stock <a href=\"https:\/\/medsbase.com\/el\/avonza\/\">Avonza (TDF \/ lamivudine \/ efavirenz)<\/a> for cost-conscious patients in whom the older TDF formulation&#8217;s renal profile is clinically acceptable.<\/p>\n<p class=\"medsbase-link-boost-2026-05-21\" data-marker=\"mb-link-boost-tavin-em\">Patients tolerating <a href=\"https:\/\/medsbase.com\/el\/tenvir-af\/\">Tenvir AF (tenofovir alafenamide 25 mg)<\/a> but seeking a lower-cost daily PrEP option without the TAF\/FTC premium may consider <a href=\"https:\/\/medsbase.com\/el\/tavin-em\/\">Tavin EM (tenofovir disoproxil 300 mg + emtricitabine 200 mg)<\/a>, the older TDF\/FTC PrEP backbone with the largest evidence base.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ad\u03c2 \u0395\u03bd\u03b1\u03bb\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ad\u03c2<\/h3>\n<p>\u0386\u03bb\u03bb\u03b1 \u03c0\u03c1\u03bf\u03ca\u03cc\u03bd\u03c4\u03b1 \u03c3\u03b5 <strong>\u03a7\u03c1\u03cc\u03bd\u03b9\u03b5\u03c2 \u03a0\u03b1\u03b8\u03ae\u03c3\u03b5\u03b9\u03c2<\/strong> \u03c0\u03bf\u03c5 \u03bf\u03b9 \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2 \u03b5\u03be\u03b5\u03c4\u03ac\u03b6\u03bf\u03c5\u03bd \u03b5\u03c0\u03af\u03c3\u03b7\u03c2:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/ebasil\/\">Ebasil<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/budecort-inhaler\/\">Budecort Inhaler<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/fluvoxin\/\">Fluvoxin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/arkamin-h\/\">Arkamin-H<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/ivepred\/\">Ivepred<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 \u0394\u03b9\u03b1\u03c7\u03b5\u03b9\u03c1\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03c4\u03b7 \u03bc\u03cc\u03bb\u03c5\u03bd\u03c3\u03b7 \u03b1\u03c0\u03cc HIV<br \/>\n\u2705 \u039c\u03b5\u03b9\u03ce\u03bd\u03b5\u03b9 \u03c4\u03bf \u03b9\u03b9\u03ba\u03cc \u03c6\u03bf\u03c1\u03c4\u03af\u03bf<br \/>\n\u2705 Protects kidneys<br \/>\n\u2705 Decreases bone loss<br \/>\n\u2705 \u0392\u03b5\u03bb\u03c4\u03b9\u03ce\u03bd\u03b5\u03b9 \u03c4\u03b7\u03bd \u03c0\u03bf\u03b9\u03cc\u03c4\u03b7\u03c4\u03b1 \u03b6\u03c9\u03ae\u03c2<\/p>\n<p><strong>Tenvir AF<\/strong> \u03c0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 <strong>Tenvir<\/strong> <strong>Alafenamide<\/strong>.<\/p>","protected":false},"featured_media":60777,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3334,3304],"product_tag":[3335,4920,4921],"class_list":{"0":"post-60776","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-hepatitis-medication","9":"product_cat-hiv-medication","10":"product_tag-tenofovir","11":"product_tag-tenofovir-alafenamide","12":"product_tag-tenvir-af","14":"first","15":"instock","16":"shipping-taxable","17":"purchasable","18":"product-type-variable","19":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/60776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=60776"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/60777"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=60776"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=60776"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=60776"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=60776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}